Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (141-150 of 466) with videos related to

Pageof 47
Sort By:
Blood|August 21, 2008
MYC stimulates EZH2 expression by repression of its negative regulator miR-26aSandrine Sander, Lars Bullinger, Kay Klapproth, et al.
Cancer Research|February 22, 2012
miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cellsValentina Kovaleva, Rodrigo Mora, Yoon Jung Park, et al.
Hemasphere|February 26, 2026
Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemiaRaúl Córdoba, Stephan Stilgenbauer, Paolo Ghia, et al.
Haematologica|April 16, 2016
Krüppel-like factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signalingKatharina Filarsky, Angela Garding, Natalia Becker, et al.
Blood|August 12, 2008
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-upThorsten Zenz, Alexander Kröber, Katrin Scherer, et al.
Leukemia & Lymphoma|December 10, 2020
No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisibJacqueline C Barrientos, Peter Hillmen, Gilles Salles, et al.
Haematologica|March 11, 2021
Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapyMarc Zapatka, Eugen Tausch, Selcen Öztürk, et al.
Haematologica|March 4, 2014
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trialsValentin Goede, Paula Cramer, Raymonde Busch, et al.
Blood|October 24, 2002
Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cellTiemo Katzenberger, Andreas Lohr, Stephan Schwarz, et al.
Cancers|June 16, 2019
Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic LeukemiaLena Schulze-Edinghausen, Claudia Dürr, Selcen Öztürk, et al.
Pageof 47

Showing results (141-150 of 466) with videos related to

Sort By:
Pageof 47
Blood|August 21, 2008
MYC stimulates EZH2 expression by repression of its negative regulator miR-26aSandrine Sander, Lars Bullinger, Kay Klapproth, et al.
Cancer Research|February 22, 2012
miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cellsValentina Kovaleva, Rodrigo Mora, Yoon Jung Park, et al.
Hemasphere|February 26, 2026
Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemiaRaúl Córdoba, Stephan Stilgenbauer, Paolo Ghia, et al.
Haematologica|April 16, 2016
Krüppel-like factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signalingKatharina Filarsky, Angela Garding, Natalia Becker, et al.
Blood|August 12, 2008
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-upThorsten Zenz, Alexander Kröber, Katrin Scherer, et al.
Leukemia & Lymphoma|December 10, 2020
No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisibJacqueline C Barrientos, Peter Hillmen, Gilles Salles, et al.
Haematologica|March 11, 2021
Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapyMarc Zapatka, Eugen Tausch, Selcen Öztürk, et al.
Haematologica|March 4, 2014
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trialsValentin Goede, Paula Cramer, Raymonde Busch, et al.
Blood|October 24, 2002
Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cellTiemo Katzenberger, Andreas Lohr, Stephan Schwarz, et al.
Cancers|June 16, 2019
Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic LeukemiaLena Schulze-Edinghausen, Claudia Dürr, Selcen Öztürk, et al.
Pageof 47